Givosiran is a subcutaneously administered RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyria (AHP). Where it is approved, it is marketed as GIVLAARI® (givosiran).
To be eligible to seek access to givosiran through the early access program (EAP), participants must meet certain requirements, including, but not limited to:
If you are a patient interested in participating, please speak with your physician about the potential benefits and risks of taking part in the program.
If you are a patient living in a country where givosiran is not commercially available and are interested in seeking access to givosiran through the EAP, please speak with your physician. Alnylam can only respond to a physician requesting access to givosiran on behalf of a patient in his/her care.
If you are a physician who is seeking to obtain access to givosiran for a patient in your care, please contact managedaccess@clinigengroup.com
If you are a physician or patient and have a medical question, please contact medinfo@alnylam.com.